Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2004-11-08
2008-08-05
Tucker, Zachary C (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S353000
Reexamination Certificate
active
07407958
ABSTRACT:
Compounds of the formula:wherein R1, R2, R3, A1 and A2 are as defined herein, which are used advantageously in inhibiting the TGF-β and/or activin signaling pathway in mammals.
REFERENCES:
patent: 6465493 (2002-10-01), Burgess et al.
patent: 6906089 (2005-06-01), Gaster et al.
patent: 7153872 (2006-12-01), Munchhof et al.
patent: 2004/0106608 (2004-06-01), Munchhof et al.
patent: 02096875 (2002-12-01), None
Vippagunta et al, “Crystalline Solids” Advanced Drug Delivery Reviews, vol. 48, pp. 3-26 (2001).
Gavezzotti, “Are Crystal Structures Predictable?” Accounts of Chemical Research, vol. 27, pp. 309-314 (1994).
de Gouville and Huet “Inhibition of ALK5 as a New Approach to Treat Liver Fibrotic Diseases” Drug News & Perspectives, vol. 19(2), pp. 85-90 (2006).
Hans Bundgaard, Design of Prodrugs, p. 1. © 1985 Elsevier Science Publishers.
Graham and Peng, “Activin Receptor-Like Kinases: Structure, Function and Clinical Implications” Endocrine, Metabolic & Immune Disorders—Drug Targets, vol. 6, pp. 45-58 (2006).
Wahab, N.A. et al.,Biochem. J. 316: 985-992 (1996).
Broekelmann, T. J. et al.,Proc. Natl. Acad. Sci. USA88: 6642-6646 (1991).
Jagirdar, J. et al.,Environ.Health Perspect.105: 1197-1203 (1997).
Wang, Q et al.,Thorax54: 805:812 (1999).
Sanderson, N. et al.,Proc. Natl. Acad. Sci. USA 92: 2572-2576 (1995).
McCaffrey, T.A. et al.J. Clin. Invest.96: 2667-2675 (1995).
Shah, M.,J. Cell. Sci. 108: 985-1002 (1995).
Hojo, M. et al.,Nature397: 530-534 (1999).
Pawlowski, J.E., et al.,J. Clin. Invest. 100: 639-648 (1997).
Munz, B. et al.,EMBO J. 18: 5205-5215 (1999).
Rosendahl, A. et al.,Am. J. Respir. Cell Mol. Biol. 25: 60-68 (2001).
Matzuk, M. M. et al.,Proc. Natl. Acd. Sci. USA91: 8817-8821 (1994).
Cipriano, S. C. et. al.,Endocrinology141: 2319-2327 (2000).
Dahly, A. J. et al.,Am J. Physiol. Regul. Integr.. Comp. Physiol. 283: R757-767.
Wahab, N.A. et al.,Biochem. J. 316:985-992 (1996).
Current Therapeutic Research, 66, 266-278 (2005) (Bicik et al).
Eddy, A.A., J.Am. Soc. Nephrol., 7:2495-2508 (1996).
Shihab, F.S. et al.,J. AM, Soc. Nephrol. 6:286-294 (1995).
J Gastroenterol Hepatol 18(12):1332-1344, 2003 (Haber et al).
Gastroenterology 2004; 127:1565-1577 (Konstantinos et al).
Rube, C.E. et al.,Int. J. Radiat. Oncol. Biol. Phys. 47:1033-1042 (2000) Cytokine & Growth Factor Reviews 14(2003) 537-550.
European Journal of Pharmacology 426(2001) 113-121 (Corbel et al).
Mechanisms of Development 112 (200) 69-77 (Grunder et al).
Broekelmann, T. J. et al.,Proc. Natl. Acad. Sci. USA88:6642-6646 (1991).
Ning, W. et al.,Proc. Natl. Acad. Sci. USA101:14895-14900 (2004).
Exp Lung Res. Jan.-Mar. 1992; 18(1):29-43 (Phan and Kunkel).
Masaki Ikeuchi,Cardiovascular Research, 64(3), 526-535 (2004).
Anne M. Deschamps, Cardiovascular Research, 69(3), 666-676 (2006).
K. Meurrens, Cardiovascular Research, 76(2), 311-322 (2007.
Razi Khan, Immunology, 118, 10-24 (2006).
DeLisa Fairweather,Am J Pathol. 165(6): 1883-1894 (2004).
Bo Jian, The Annals of Thoracic Surgery, 75(2), 457-465 (2003).
Marta Ruiz-Ortega, Cardiovascular Research, 74(2), 196-206 (2007.
Cytokine & Growth Factor Reviews 18 (2007) 279-286 (Redondo et al).
David J. Grainger, Cardiovascular Research, 74(2), 213-222 (2007).
Mark J. Elder, Experimental Eye Research, 65(2), 165-176 (1997).
Peter Esser, Experimental Eye Research, 65(3), 365-378 (1997).
Perspectives in Vascular Surgery and Endovascular Therapy 2006, 18(1), 55-62 (Faler et al).
Saed, G. M. et al.,Wound Repair Regeneration7:504-510 (1999).
Clinics in Dermatology (2005) 23, 480-490 (Uwe-Frithof and Haustein).
FASB J. 11, 851-857 (1997) (Leonarduzzi et al).
Chris T. Derk, Autoimmunity Reviews, 2(4), 181-191 (2003).
Mathieu C. Tamby, Autoimmunity Reviews, 2(4), 152-157 (2003).
Marinos C. Dalakas, International Immunopharmacology, 6(4), 550-556 (2006).
E. N. Blaney Davidson, Osteoarthritis and Cartilage, 15(6), 597-604 (2007).
Trinity J. The Journal of Urology, 163(6), 1992-1998 (2000).
Prdeep Salins, Neuroscience Letters, In Press, Accepted Manuscript, Available online Oct. 30, 2007.
Anita B. Roberts, Cytokine & Growth Factor Reviews, 17(1-2), 19-27 (2006).
Martin, M. et al.,Int. J. Radiat. Oncol. Biol. Phys. 47:277-290 (2000)Int. J. Radiat. Oncol. Biol. Phys. 47:1033-1042 (2000).
Vaughan, D.E.,J. Invest. Med. 46:370-376 (1998).
An Young Jae
Bang Yung-Jue
Cho Il-Sang
Choi Joon Hun
Kim Dae-Kee
Beaumont William E.
EWHA University - Industry Collaboration Foundation
SK Chemicals Co. Ltd.
Tucker Zachary C
LandOfFree
2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4012661